Home > Insider Trading > Filing (0001209191-17-053141)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333482	J Kimberly Popovits	301 Penobscot Dr. Redwood City CA 94063	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-09-14	5,000	$17.33	46,132	No	4	M	Direct
Common Stock	Disposition	2017-09-14	5,000	$31.00	41,132	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2017-09-14	5,000	$0.00	0	$17.33

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
32,900		2018-12-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,298	Indirect	Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits
Common Stock	16,825	Indirect	Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.
Common Stock	237,312	Indirect	Held by the Popovits 2010 Trust

Footnotes

Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Reporting person transferred 37,925 shares from Directly Held to Indirectly Held on August 22, 2017.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017.
Represents weighted average sale price. Actual sale prices ranged from $30.77 to $31.27.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.